Switch theme
Sign up to access all valuation multiples
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
2015
108
Last FY Revenue n/a
LTM EBITDA -$191M
$634M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pharvaris has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$191M.
In the most recent fiscal year, Pharvaris achieved revenue of n/a and an EBITDA of -$145M.
Pharvaris expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pharvaris valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$191M | XXX | -$145M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$195M | XXX | -$146M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$186M | XXX | -$134M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pharvaris's stock price is $17.
Pharvaris has current market cap of $899M, and EV of $634M.
See Pharvaris trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $634M | $899M | XXX | XXX | XXX | XXX | $-3.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pharvaris has market cap of $899M and EV of $634M.
Pharvaris's trades at n/a EV/Revenue multiple, and -4.4x EV/EBITDA.
Equity research analysts estimate Pharvaris's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pharvaris has a P/E ratio of -5.4x.
See valuation multiples for Pharvaris and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $899M | XXX | $899M | XXX | XXX | XXX |
| EV (current) | $634M | XXX | $634M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -3.7x | XXX | -4.4x | XXX | XXX | XXX |
| EV/EBIT | -3.7x | XXX | -4.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.4x | XXX | -6.7x | XXX | XXX | XXX |
| EV/FCF | -4.5x | XXX | -5.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPharvaris's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.3M for the same period.
Pharvaris's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pharvaris's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pharvaris and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pharvaris acquired XXX companies to date.
Last acquisition by Pharvaris was XXXXXXXX, XXXXX XXXXX XXXXXX . Pharvaris acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pharvaris founded? | Pharvaris was founded in 2015. |
| Where is Pharvaris headquartered? | Pharvaris is headquartered in United States of America. |
| How many employees does Pharvaris have? | As of today, Pharvaris has 108 employees. |
| Who is the CEO of Pharvaris? | Pharvaris's CEO is Mr. Berndt Modig. |
| Is Pharvaris publicy listed? | Yes, Pharvaris is a public company listed on NAS. |
| What is the stock symbol of Pharvaris? | Pharvaris trades under PHVS ticker. |
| When did Pharvaris go public? | Pharvaris went public in 2021. |
| Who are competitors of Pharvaris? | Similar companies to Pharvaris include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Pharvaris? | Pharvaris's current market cap is $899M |
| Is Pharvaris profitable? | Yes, Pharvaris is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pharvaris? | Pharvaris's last 12 months EBITDA is -$191M. |
| What is the current EV/EBITDA multiple of Pharvaris? | Current EBITDA multiple of Pharvaris is -3.7x. |
| What is the current FCF of Pharvaris? | Pharvaris's last 12 months FCF is -$159M. |
| What is the current EV/FCF multiple of Pharvaris? | Current FCF multiple of Pharvaris is -4.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
